← ANALYST RATINGS · TIPRANKS
MacroGenics (MGNX): analyst forecast and price target
Analyst consensus
Moderate Buy2 Buy2 Hold0 Sell
Ratings of 4 analysts in the last 3 months · top analysts only12-month forecast
Based on 4 price targets given in the last 3 months, the average target is $7.00, the highest $11.00, the lowest $4.00. The average is +115.4% from the last price of $3.25.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $4.00 → $3.50−12.5% | Hold | +7.7% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $4.00 → $3.50−12.5% | Hold | +7.7% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $4.00 → $3.50−12.5% | Hold | +7.7% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $4.00 → $3.00−25.0% | Hold | −7.7% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $4.00 → $3.50−12.5% | Hold | +7.7% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $4.00 → $3.50−12.5% | Hold | +7.7% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| Mayank Mamtani★★★★★★★★★★#2653 · hits 38% · avg +5.8% | B. Riley Securities | $9.00 → $11.00+22.2% | Buy | +238.5% | Reiterated | 17.08.26on TipRanks 09:20 | −3.3%next day +1.4% · 5 days +0.2% | ↗ |
| Etzer Darout★★★★★★★★★★#105 · hits 63% · avg +31.4% | Barclays | $6.00 | Buy | +84.6% | Reiterated | 14.08.26on TipRanks Aug 17 04:55 | +3.6%next day −3.3% · 5 days −1.5% | ↗ |
| Stephen Willey★★★★★★★★★★#1608 · hits 45% · avg +8.1% | Stifel Nicolaus | $4.00 | Hold | +23.1% | Reiterated | 14.08.26on TipRanks 07:30 | +3.6%next day −3.3% · 5 days −1.5% | ↗ |
| Tara Bancroft★★★★★★★★★★#361 · hits 55% · avg +30.3% | TD Cowen | — | Hold | — | Reiterated | 13.08.26on TipRanks Aug 17 05:56 | +0.8%next day +3.6% · 5 days +1.7% | ↗ |
| Robert Burns★★★★★★★★★★#272 · hits 52% · avg +25.9% | H.C. Wainwright | — | Hold | — | Reiterated | 07.05.26on TipRanks 06:30 | −2.0%next day +1.2% · 5 days +39.2% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering MacroGenics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $7.00 at a price of $3.86 (+81.3%); now: $7.00 at $3.25 (+115.4%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 2 | 1 | 1 | 1 |
| Buy | 1 | 0 | 0 | 1 | 1 | 1 |
| Hold | 4 | 2 | 3 | 3 | 3 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 04.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.32 (from $-0.60 to $-0.08). Last quarter: $0.31.
Sales
Next quarter’s sales estimate — $39M (from $10M to $62M). Last quarter: $33M.
Best top-analyst consensus in the sector · Healthcare
About MacroGenics
- CEO: Eric Risser
- Employees: 293
- 9704 Medical Center Drive, Rockville, MD, 20850, US
- www.macrogenics.com
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
Data from the stock’s TipRanks forecast page, read 16 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗